MONDAY, Nov. 25, 2019 (HealthDay News) — For three commercial panels for prostate cancer prognosis, gene expression differs for European-American men (EAM) and African-American men (AAM), according to a study published online Nov. 22 in Cancer Epidemiology, Biomarkers & Prevention.

Jordan H. Creed, from the H. Lee Moffitt Cancer Center and Research Institute in Tampa, Florida, and colleagues examined differences in gene expression between EAM and AAM for three commercially available panels recommended for prostate cancer prognosis. Radical prostatectomy specimens were provided by 232 EAM and 95 AAM patients. Gene expression was quantified for 60 genes spanning the Oncotype DX Prostate, Prolaris, and Decipher panels.

The researchers found that AAM and EAM had similar clinical and pathological features. For 48 percent of genes measured, differential expression by race was observed, although the magnitudes of the differences were small. Compared with Prolaris, for Oncotype DX and Decipher, coexpression patterns were more strongly preserved by race group. For Oncotype DX, poorer prognosis was estimated in EAM versus AAM, while negligible prognostic differences were predicted using Prolaris or Decipher.

“Until the risk prediction accuracy of the tests has been thoroughly studied in African-American patients, we urge caution in their use for clinical decision making,” a coauthor said in a statement. “We hope that our report escalates interest in validating the utility of genomic risk predictors in African-American men.”

Abstract/Full Text (subscription or payment may be required)

Copyright © 2019 HealthDay. All rights reserved.